Oncology News
Oncology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?


Article ID

Home
General Oncology
Messages
Conferences
Jobs
Newsletters
My Library
Topics in
Oncology
        Alternative Therapies
        Anemia/Polycythemia
        BMT/SCT
        Basic Science/Genetics
        Bone/Cartilage
        Breast
        Carcinogenesis
        Coagulation/Bleeding Dz
        Colorectal Cancer/Polyps
        Dermatologic Oncology
        Diagnostics/Radiology
        Economics of Medicine
        Endocrine Oncology
        GI Oncology
        Gynecologic Oncology
        Head and Neck
        Hepatobiliary/Pancreas
        Leukemia/Lymphoma
        Lung/Thoracic Oncology
        Myeloproliferative Dz
        Neurologic Oncology
        Pain Management/
    Palliative Care
        Pediatric Heme/Oncology
        Pharmacology/Therapy
        Popular Press
        Renal/Urologic
        Side Effects
        Soft Tissue/Sarcoma
        Transfusion Medicine
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
Top Ten Searches
brca1  brca1
prostate-specific antigen  prostate-specific antigen
sclc  sclc
fobt  fobt
egd  egd
bmi  bmi
dysplasia  dysplasia
hematologic  hematologic
ovarian  ovarian
hcc  hcc
 
Sponsor
MDLinx Email Article

To email this article, enter your own "From Email" address,
the recipient's "To Email" address, and click the "Send Email" button.
You may send to up to 5 email addresses.
*From Email:  
*To Email:  
To Email:  
To Email:  
To Email:  
To Email:  
Immunocytochemical detection of occult tumor cells in the bone marrow: prognostic impact on early stages of lung cancer
Nosotti M et al. - Immunocytochemical analysis detects occult tumor cells in the bone marrow of at least 25% of pt surgically treated for stage I and II non-small-cell lung cancer (NSCLC); these occult tumor cells have no impact on the disease-free interval

Methods

  • Study to verify the prognostic impact of occult tumor cells in the bone marrow of stage I and II NSCLC pts using cytokeratin as a micrometastatic marker
  • Review of 152 pts with stage I and II NSCLC who had radical surgery by pulmonary lobectomy
  • Anti-cytokeratin 18 antibody stain of bone marrow from fragments of resected ribs and primary tumors
  • Controls: 14 bone marrow specimens from pts without malignancy
  • End point: cancer recurrence

Results
  • All primary tumors positive for cytokeratin
  • Occult tumor cells found in 38 bone marrow specimens (25%)
  • Prevalence of occult tumor cells was not related to age, gender, tumor stage, histologic differentiation or grade
  • Mean follow-up was 35.3 mo
  • Recurrence in 68 pts; mean time to recurrence: 21.2 mo
  • General disease-free interval not related to presence of occult tumor cells in bone marrow, which did not change with pts grouped by tumor stage
  • Stage was the best predictor of cancer recurrence
[more...]
Sponsor

Read a Different Specialty

Oncology Articles
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pain
Pediatrics
Practice Management
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Profession Index

Oncology Articles
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2009 MDLinx, Inc.